We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Connect Biopharma Holdings Limited Sponsored ADR (CNTB - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Connect Biopharma Holdings Limited Sponsored ADR is a member of our Medical group, which includes 1087 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Connect Biopharma Holdings Limited Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CNTB's full-year earnings has moved 39.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, CNTB has returned 29.1% so far this year. Meanwhile, the Medical sector has returned an average of -7.6% on a year-to-date basis. As we can see, Connect Biopharma Holdings Limited Sponsored ADR is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is DexCom (DXCM - Free Report) . The stock is up 0.7% year-to-date.
The consensus estimate for DexCom's current year EPS has increased 16.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Connect Biopharma Holdings Limited Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, which includes 528 individual stocks and currently sits at #47 in the Zacks Industry Rank. On average, stocks in this group have lost 22.4% this year, meaning that CNTB is performing better in terms of year-to-date returns.
DexCom, however, belongs to the Medical - Instruments industry. Currently, this 94-stock industry is ranked #72. The industry has moved -4.9% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Connect Biopharma Holdings Limited Sponsored ADR and DexCom as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Connect Biopharma Holdings Limited Sponsored ADR (CNTB - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Connect Biopharma Holdings Limited Sponsored ADR is a member of our Medical group, which includes 1087 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Connect Biopharma Holdings Limited Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CNTB's full-year earnings has moved 39.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, CNTB has returned 29.1% so far this year. Meanwhile, the Medical sector has returned an average of -7.6% on a year-to-date basis. As we can see, Connect Biopharma Holdings Limited Sponsored ADR is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is DexCom (DXCM - Free Report) . The stock is up 0.7% year-to-date.
The consensus estimate for DexCom's current year EPS has increased 16.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Connect Biopharma Holdings Limited Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, which includes 528 individual stocks and currently sits at #47 in the Zacks Industry Rank. On average, stocks in this group have lost 22.4% this year, meaning that CNTB is performing better in terms of year-to-date returns.
DexCom, however, belongs to the Medical - Instruments industry. Currently, this 94-stock industry is ranked #72. The industry has moved -4.9% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Connect Biopharma Holdings Limited Sponsored ADR and DexCom as they attempt to continue their solid performance.